Skip to Content
Merck
  • Design, synthesis and biological evaluation of novel nitroaromatic compounds as potent glutathione reductase inhibitors.

Design, synthesis and biological evaluation of novel nitroaromatic compounds as potent glutathione reductase inhibitors.

Bioorganic & medicinal chemistry letters (2011-07-29)
Reşit Çakmak, Serdar Durdagi, Deniz Ekinci, Murat Sentürk, Giray Topal
ABSTRACT

Discovery of GR inhibitors has become very popular recently due to antimalarial and anticancer activities. In this study, the synthesis and GR inhibitory capacities of novel nitroaromatic compounds (NCs) (1-3) were reported. Some commercially available molecules were also tested for comparison reasons. The novel NCs were obtained in high yields using simple chemical procedures and exhibited much potent inhibitory activities against GR at low micromolar concentrations with K(i) values ranging from 0.211 to 4.57 μM as compared with well-known agents. Inhibition mechanism was assessed as being due to occlusion of the active site entrance by means of the NCs. Molecular docking results have shown that docking poses of ligands are able to construct binding interactions with the essential amino acids.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Lysine, ≥98% (TLC)
Sigma-Aldrich
Nifedipine, ≥98% (HPLC), powder
Sigma-Aldrich
L-Lysine, crystallized, ≥98.0% (NT)
Sigma-Aldrich
L-Glutamic acid, FCC
Sigma-Aldrich
L-Glutamic acid, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
L-Glutamic acid, from non-animal source, meets EP testing specifications, suitable for cell culture, 98.5-100.5%
Sigma-Aldrich
L-Glutamic acid, ReagentPlus®, ≥99% (HPLC)
Supelco
L-Glutamic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland